Content Detail

• Content META

  Title	Earnings call transcript: Accuray's Q2 2026 results show revenue dip, stock steady
  ID	30470379
  External ID	b3513f2f4d82ec54d2093ccf83e43ff2
  Author
  Published Date	Feb. 4, 2026, 4:15 p.m.
  Summary	Earnings call transcript: Accuray's Q2 2026 results show revenue dip, stock steady
  Tags
  URL	https://www.investing.com/news/transcripts/earnings-call-transcript-accurays-q2-2026-results-show-revenue-dip-stock-steady-93ch-4486199
  Sentiment	Negative: 0.97261    Neutral: 0.01278    Positive: 0.01461
  Relevance	0.08791

• Content Details

  Content ID	37761519
  Key	f3a6400e-412e-4b6b-a633-e7b4d0869e61
  Content	Accuray Incorporated reported its second-quarter earnings for fiscal year 2026, revealing a dip in revenue but stable earnings per share (EPS) compared to forecasts. The company posted an EPS of -$0.11, matching analysts' expectations, while revenue came in at $102.2 million, falling short of the $109.11 million forecast. Despite the revenue miss, Accuray's stock remained stable in after-hours trading, holding steady at $0.752 per share, reflecting a 0.65% increase from the previous close. Key Takeaways Accuray's Q2 2026 revenue fell 12% year-over-year, with significant declines in product revenue. The company maintained its EPS forecast, avoiding any surprise in earnings. Stock price remained stable post-earnings, indicating market resilience despite revenue shortfall. Revised FY2026 revenue guidance lowered, reflecting current market challenges. Operational restructuring aims to improve profitability with a 15% workforce reduction. Company Performance Accuray's performance in the second quarter of fiscal 2026 highlighted challenges, particularly in product revenue, which decreased by 26% year-over-year. The company experienced a decline in gross margin, dropping to 23.5% from 36.1% the previous year. Despite these setbacks, service revenue saw a modest increase of 4%. The company's order backlog remains strong, suggesting potential for future revenue stabilization. Financial Highlights Revenue: $102.2 million, down 12% year-over-year Product Revenue: $45 million, down 26% year-over-year Service Revenue: $57.2 million, up 4% year-over-year Gross Margin: 23.5%, down from 36.1% year-over-year Adjusted EBITDA: Loss of $1.9 million, compared to a $9.6 million profit in the previous year Earnings vs. Forecast Accuray's EPS of -$0.11 met the forecast, resulting in no surprise for investors. However, the revenue of $102.2 million fell short of the $109.11 million forecast, representing a 6.33% miss. This revenue shortfall contrasts with the company's past performance, where it has occasionally exceeded expectations. Market Reaction Following the earnings release, Accuray's stock price remained stable in after-hours trading, closing at $0.752 per share, a 0.65% increase from the last close. The stock's performance reflects market confidence in the company's strategic initiatives despite the revenue miss. Accuray's current price is closer to its 52-week low of $0.722, suggesting potential for recovery. Outlook & Guidance Accuray revised its full-year 2026 revenue guidance to $440-$450 million, down from the previous range of $471-$485 million. The company also adjusted its EBITDA guidance to $22-$25 million, reflecting ongoing operational challenges. Accuray aims for a high single-digit EBITDA margin within nine months, with long-term goals of achieving double-digit margins. Executive Commentary CEO Steve La Neve emphasized the company's commitment to growth and profitability, stating, "Our objectives are clear: drive top-line growth, improve profitability, and create lasting value for patients, providers, and shareholders." He also highlighted the company's focus on product differentiation and global market expansion. Risks and Challenges Geopolitical tensions, especially in China, may impact demand and market access. Tariff impacts continue to pressure product margins and overall profitability. Restructuring and workforce reductions could lead to operational disruptions. Dependence on distributor networks poses risks if partnerships falter. Macroeconomic factors, including hospital capital expenditure trends, could affect future growth. Q&A During the earnings call, analysts inquired about the impact of geopolitical challenges in China and the slower licensing process. Questions also focused on product margin pressures due to tariffs and the company's plans to expand its service portfolio. Accuray confirmed that the hospital capital expenditure environment remains stable, providing some reassurance to investors. Full transcript - Accuray Incorporated (ARAY) Q2 2026: Conference Operator : Good afternoon and welcome to Accuray's conference call to review financial results for the second quarter of fiscal year 2026, which ended December 31st of 2025. All participants will be in a listen-only mode. Should you need assistance, please signal conference specialists by pressing the star key followed by zero. After today's presentation, there will be an opportunity to ask questions. To ask a question, you may press star then one on your telephone keypad, and to withdraw your question, please press star then two. Please note this event is being recorded. I would now like to turn the conference over to Mr. Steve Monroe. Please go ahead. Steve Monroe, Investor Relations, Accuray : Thank you and good afternoon, everyone. Welcome to Accuray's conference call to review financial results for the second quarter of fiscal year 2026, which ended December 31st, 2025. During our call this afternoon, management will review recent corporate developments. Joining us on today's call are Steve La Neve, Accuray's President and Chief Executive Officer, and Ali Pervaiz, Accuray's Chief Financial Officer. Before we begin, I would like to remind you that our call today includes forward-looking statements. Actual results may differ materially from those contemplated or implied by these forward-looking statements. Factors that could cause these results to differ materially are outlined in the press release we issued just after the market closed this afternoon, as well as in our filings with the Securities and Exchange Commission. We base the forward-looking statements on this call on the information available to us as of today's date. We assume no obligation to update any forward-looking statements as a result of new information or future events, except to the extent required by applicable securities laws. Accordingly, you should not put undue reliance on any forward-looking statements. A few housekeeping items for today's call: all references to a specific quarter in the prepared remarks are to our fiscal year quarters. For example, statements regarding our second quarter refer to our fiscal second quarter ended December 31st, 2025. Additionally, there will be a supplemental slide deck to accompany this call, which you can access by going directly to Accuray's Investor Relations page at investors.accuray.com. As you review our prepared remarks and guidance today, please note that our outlook represents our current estimates and reflects the operating environment as we understand it today, including current tariff impacts and geopolitical conditions. As always, the situation remains dynamic, and we will continue to update investors as visibility improves. With that, let me turn the call over to Accuray's Chief Executive Officer, Steve La Neve. Steve? Steve La Neve, President and Chief Executive Officer, Accuray : Thank you, Steve. Good afternoon, everyone, and thank you for joining us. I want to begin by recognizing the dedication of our employees and the trust of our customers. Over the last 90 days, I've engaged deeply with our teams and customers across our regions, and my conviction in Accuray's opportunity has never been stronger. The more time I spend in the field, the clearer it becomes of the opportunity to accelerate top-line growth and to meaningfully expand profitability in the years ahead. Importantly, these insights are already translating into action. The discussions I've had have directly shaped our product and service strategy and the changes we are implementing to support those strategies, from right-sizing our cost structure to re-energize our commercial organization to more surgically prioritizing product and service investments. I recognize the unmistakable need to streamline how we operate and execute as we grow a global installed base that now spans more than 80 countries. Framing today's discussion, as many of you saw, in mid-December we announced a comprehensive strategic, operational, and organizational transformation plan designed to sharpen accountability, tighten cost control, and accelerate execution while positioning Accuray for sustained, profitable growth. Today, I want to provide an update on the plan and the progress we have made on some strategic initiatives we are pursuing, as well as updates on some operational actions we introduced in December, which are geared towards improving the competitiveness, growth prospects, and profitability of our overall business. I will then discuss the quarter's performance and some insight into the next 12 months. Ali will then discuss the detailed financial results. Our plan started with establishing clear product and service strategies as well as the enablers that we believe are critical to achieving these strategies. The first of those enablers was the right-sizing of our cost structure while improving process efficiency and use of technology. This was coupled with an organizational realignment that centralized certain functions, outsourced non-core activities, and emphasized accountability, control, speed of decision-making, and selling. At the same time, we reallocated engineering resources to focus on high ROI programs to integrate third-party solutions and to better reflect the voice of our customers. These elements of our transformation plan targeted an approximately $25 million improvement in annualized operating profitability, which included a workforce reduction of about 15% and are expected to deliver roughly $12 million of benefit in fiscal 2026, with substantially all initiatives implemented by fiscal year-end. We also indicated that we expect approximately $10 million of restructuring charges across the second, third, and fourth fiscal quarters related to workforce reductions, facility consolidation, contract terminations, and other implementation costs. These measures are not, however, ends unto themselves, but rather are enablers of our long-term strategies intended to build substantial value going forward as we take disciplined actions to strengthen our commercial execution and build a more predictable, higher-margin growth engine. Let me briefly highlight a few examples of the initiatives already underway. First, we are working to expand and diversify our service portfolio. We are shifting towards a comprehensive solutions-oriented offering that increases customer uptime, enhances system performance, and drives higher-margin recurring revenue while addressing customer needs and increasing lifecycle engagement across the installed base. Second, we are working towards a more structured distributor partnership and management program. Global markets where distributors are central to our reach, we are in the process of putting in place robust systems, clear performance standards, tighter alignment, more transparency, and critically, better support models to ensure consistent, high-quality commercial execution. Third, our determination to meet or exceed our customers' expectations has sometimes resulted in us not billing or collecting for services and service levels we have provided. We are now designing and implementing systems, processes, and controls to help ensure we are compensated to the extent to which we are entitled for the work our teams deliver every day. As a fourth example, we are on a path to optimizing pricing across our product and service portfolio. This work will help ensure that our pricing reflects the true clinical and economic value our technology delivers, will facilitate our winning competitive bids at appropriate margins, and should be reflected in our sales and margin growth over time. Collectively, these are the types of actions that, as they are implemented and begin to take effect, are intended to represent a step change in how we drive growth: creating a more diversified revenue mix, a more resilient recurring base, and a more disciplined commercial organization. Strong commercial leadership is also a critical enabler of our strategies, and we hope to announce in the period ahead the appointment of a new global Chief Commercial Officer with a track record and approach that align with our long-term objectives. Overall, these initiatives are already in motion and would play a critical role in strengthening our top line, improving profitability, and supporting sustainable value creation going forward. Against the backdrop of our transformation, our customer conversations have been strikingly consistent across geographies. Health systems appear to be prioritizing three things: reliability, interoperability, and patient throughput. This clarity is helping us sequence our product roadmap and service investments with much greater discipline. From an operating rhythm perspective, we have tightened weekly and monthly financial and operating reviews around orders, revenue, margins, service performance, and cash, highlighting KPIs that are critical to improve business performance, enabling faster corrective actions where needed. This rhythm supports the accountability and execution pace we committed to in December. Lastly, from a people and culture point of view, our leadership team knows that we need to emphasize and incentivize teamwork, cross-functional collaboration, data-driven decision-making, and a heightened sense of urgency in order to create a performance-driven environment. I believe strongly that transformations succeed when they're owned by the organization. I'm proud of how our teams have leaned in, maintaining customer focus while embracing new ways of working. We are supporting our people through the transformation, and I want to thank every Accuray teammate for their resilience and professionalism. Now, turning to the quarter results. From a top-line perspective, this quarter did not meet our expectations. Our business was most notably impacted by the ongoing tariffs and the increasingly unstable geopolitical environment, particularly as it relates to China, which has been a big part of our growth story over the last couple of years. These external pressures affected both demand patterns and the timing of commercial activity in ways that have been difficult to fully anticipate. We are keeping a close eye on all of these factors and will keep you updated as we get more clarity over the next few quarters. Given the visibility we have today, we think it's prudent to reset our fiscal 2026 revenue and Adjusted EBITDA outlook for the remainder of the fiscal year. This updated guidance assumes and reflects continued volatility in China, the persistence of current tariff structures, and other ongoing headwinds, but does not assume a material worsening beyond what we are experiencing today. Our revised guidance on the revenue will be in the range of $440-$450 million, with Adjusted EBITDA guidance of $22-$25 million. This compares to our previous guidance of $471-$485 million of revenue and $31-$35 million of adjusted EBITDA. That said, the underlying trends inside the company tell a different and more encouraging story. We are beginning to translate our strategic intent into operational execution, tightening costs, streamlining decision-making, improving competitiveness, and reallocating resources toward areas where we can drive the greatest value. Despite the external headwinds, we remain firmly focused on delivering against our transformation commitments and strengthening Accuray's foundation for sustained, profitable growth. Our objectives are clear: drive top-line growth, improve profitability, and create lasting value for patients, providers, and shareholders. With that in mind, we continue to expect to reach a high single-digit adjusted EBITDA margin run rate within the next nine months and to expand that margin to double digits over the medium to long term. With that, I'll hand it over to Ali for a detailed review of our second quarter results. Ali? Thanks, Steve, and good afternoon, everyone. I would like to begin by thanking our global cross-functional teams for their continued dedication and hard work as we continue to execute on our transformation plan. Turning to the second quarter results. Net revenue for the quarter was $102.2 million, which was down 12% versus the prior year and down 13% on a constant currency basis. Product revenue for the second quarter was $45 million, down 26% overall and down 28% on a constant currency basis. As Steve mentioned, most of this decline was due to product revenue in China that was lower than expected as a result of ongoing geopolitical tensions and the impact of tariffs. On a positive note, our service business was quite resilient despite some of these weaker macro trends coming in at $57.2 million in revenue, up 4% from the prior year and up 3% on a constant currency basis. As we have mentioned on past calls, service is a key part of our recurring revenue growth strategy and continues to benefit from efforts to add to and diversify our offerings as well as continue expansion of our global install base. Product growth orders for the second quarter were approximately $66 million and represented a book-to-bill ratio of 1.5 with a trailing 12-month ratio of 1.2. We ended the second quarter with a reported order backlog of approximately $383 million defined to include only orders younger than 30 months. This represents over 18 months of product revenue, and the backlog remains diversified geographically and supported by long-term customer commitments, and we saw no order cancellations during the quarter. Our overall growth margin for the quarter was 23.5% compared to 36.1% in the prior year. This decline was primarily due to product growth margins, which were 19.7% compared to 43.5% in the prior year. The majority of the unfavorable impact to product growth margins was related to our China business. First, we had lower China margin releases compared to the prior year, which contributed 8.2 points of the decline. As a reminder, in Q2 of fiscal 2025, we released 27 units of China product following NMPA approval of the TomoC. Second, the year-over-year incremental cost from higher tariffs impacted product growth margins by approximately 6 points. Lastly, we had 5 CyberKnife shipments in the prior year versus 0 in the current quarter, which impacted product growth margins by approximately 5.4 points. Service growth margins were 26.6% compared to 27.7% in the prior year, primarily driven by higher net parts consumption. Overall, we continue to be focused on margin expansion in our service business driven by higher pricing, improved product reliability leading to lower labor costs and parts consumption, and reducing our cost to serve and the increased penetration of diverse, high-margin service offerings. Quarterly service growth margins can fluctuate due to the timing of parts consumption, which we experienced in Q2. While several of these factors are transitory, such as prior year China releases and product mix, others like tariffs may persist in the near term. Our transformation actions are designed to offset these pressures through cost reduction, operational efficiency, and margin improvement in service. Operating expenses in the second quarter were $35.6 million compared to $37.2 million in the second quarter of the prior fiscal year. The $35.6 million includes $6.1 million of one-time restructuring expenses. Stripping those out, our operating expenses declined almost 21% quarter-over-quarter. Operating loss for the quarter was $11.6 million compared to an income of $4.7 million in the prior year. The $6.1 million in restructuring charges recognized in the second quarter included severance costs and other one-time costs directly related to our restructuring and transformation plans. Adjusted EBITDA for the quarter was a loss of $1.9 million compared to positive $9.6 million in the prior year. We describe the reconciliation between GAAP net income and adjusted EBITDA in our earnings release issued today. Turning to the balance sheet, total cash, cash equivalents, and short-term restricted cash amounted to $41.9 million compared to $63.9 million at the end of last quarter, primarily due to working capital usage, cash interest, and restructuring payments. Net accounts receivable were $61 million, up $6.6 million from the prior quarter, largely due to higher sequential quarter revenue. Our net inventory balance was $151 million, down $4.5 million from the prior quarter. And with that, I'd like to hand the call back to Steve. Thank you, Ali. In closing, I continue to be excited about the opportunities Accuray has in front of it. I fundamentally believe in our differentiated product offerings and am committed to enabling access to these truly unique helical and robotic platform technologies by patients globally. As stated previously, my underlying goal is to foster a performance-driven culture that pairs innovation with execution, strengthens operational discipline, and drives sustainable, profitable growth while creating long-term value for patients, providers, and shareholders we serve. As you look ahead to the next several quarters, we believe our progress should be measured by three things: resumption of expansion of our installed base, improved cost discipline and EBITDA margin trajectory, continued resilience and margin expansion in our service business, and evidence that our operational simplification is translating into more consistent execution. I will now turn it back over to the operator for Q&A. Thank you. We will now begin the question and answer session. To ask a question, you may press star, then one on your telephone keypad. If you're using a speakerphone, please pick up your handset before pressing the keys. If at any time your question has been addressed and you would like to withdraw your question, please press star, then two. Our first question for today will come from Marie Thibault with BTIG. Please go ahead. Good evening, Steve and Ali. Thanks for taking the questions. I wanted to dig here a little bit on the revenue guidance cut. We've grown very used to Accuray having kind of a 40/60 split, 40% of revenue coming in the first half of the fiscal year, 60% in the back half. If I look at what you've done so far in the first half of this fiscal year, you're right on track with 40% for that prior guidance range. So I'm wondering what exactly you saw that's coming in the back half of the year that's sort of made you get more cautious. Is it China alone? Is there just closer visibility on timelines and other projects? Any more detail on the guidance cut because you're certainly right on track for that 40/60 that we're used to? Yeah. Hi, Marie, and thanks for the question. This is Steve. Maybe I'll just do a very gentle kind of adjustment on the 40/60 comment. I think it's typically been closer to 45/55. So maybe just that clarification there. And then with respect to China, clearly, as we stated in the remarks, the business was impacted by the ongoing tariffs and an increasingly unstable geopolitical environment that we've commented on before. And obviously, that's been a big part of our growth story over the last couple of years. And those external pressures affected both the demand patterns and the timing of our commercial activity in ways that have been difficult to fully anticipate. As you likely know, there's a process in China around quota, license, tender, and then funding. And that process flow has slowed. And so the deal dynamics have wound up being different than we had anticipated and have just become more protracted. And it's really as simple and as complicated as that. Okay. That's helpful, Steve. Thank you. And then I guess on product growth margins, I think a little light this quarter, I think related to some of the China JV timing. What should we expect on product growth margins going forward here with this new revenue range and with some of the dynamics that you've discussed? I can take that one, Marie. Thanks for the question. So look, I mean, I think in general, product growth margins are going to continue to get hit with the impact of tariffs, which is a new entrant compared to prior year, and then also just inflation that we continue to have over the last couple of years. We're certainly taking actions to combat that as part of our margin expansion plan. But the headwinds are certainly stronger than the way that we're executing against it. As it pertains to Q2 in particular, in my prepared comments, there are really three main contributors. There was a China JV release of about 8 points compared to prior year. There was a tariffs at about 6 points. And then overall product mix that was roughly another 8 points or so. And so those are really the key contributors versus prior year. Again, probably more headwinds this quarter. So I would not expect product growth margins to continue to hover in the 20% range. I would expect them to be somewhere between 20%-30%, but that's highly dependent upon the product mix that's shipped out and also dependent upon the timing of the releases, which is very China-centric. All right. Very helpful, Ali. I'll jump back in queue. Thank you. Thanks, Marie. Thank you. The next question will come from Young Lee with Jefferies. Please go ahead. All right. Great. Thanks for taking our questions. I guess maybe to start, I wanted to hear a little bit more about the new initiatives you put in for, I guess, returning the business to growth, sort of the solutions-oriented initiatives as well as the structure distributor partnerships. I guess for those, are there any potentials for disruption as things change? When do you expect us to see some results from that? And yeah, those are the questions. Thank you. Yeah. Thank you, Young. This is Steve. Appreciate the question. As we've looked at transformation and spoken about that in the past, obviously, have spent time on restructuring the organization to really position ourselves for growth. And as we had commented on before, about a 15% workforce reduction. And then looking at kind of the opposite side to the cost savings and the program redirection, really spending time on growth and looking at operating rigor and speed of decision-making, making sure that we establish clear product and service strategies, reallocating engineering sources to focus on high ROI programs. And then specifically to your point on the solutions in the service area, we think there's a great opportunity to build on what we call our select, advantage, and optimum programs. Those programs go from sort of base level to mid-level to premium-level service offerings. They go beyond break-fix and include potentially areas like training, quality support, user groups and forums, data management, real-time monitoring, software upgrades, consulting, workflow analysis, those sorts of options that we want to build into our services capabilities. It gives us steadier, we think, opportunities to drive top-line growth. It's less lumpy in nature. We think changes the way we look at that services business. The company, I think, has focused a lot on products in the past, and we see a great opportunity and a lot of lift on the service side with respect to our transformation activities. And so that's an area that we've kind of doubled down on just in terms of our staff that we've put into that area, our strategy, our structure, our systems, and think there's a lot of upside there. With respect to the dealers and distributors, have a program that looks at tiered levels, basically a pay-for-performance model. And obviously, for those dealers and distributors that do more for us, the idea would be that they enjoy better margins or transfer pricing, really. It's really about pricing. And we think the addition of a channel leader that really doubles down on looking at those channel management opportunities versus having this maybe at a higher level within the regions gives us the kind of focus and precision that we're looking for out of channel partners who do a lot for us in terms of driving revenue. And of course, with our presence in 81 countries, it would be impossible with our current scale to have directly loaded sales organizations in all those locations. And so our distributor and dealer base, obviously, are very important to us. All right. Great. Very helpful. And then we've been asking several of our companies sort of the same theme type of questions, but new calendar year. Just wanted to get your views on, I guess, from your hospital customers' perspective, how is the capital environment from their perspective, especially in places like US, China, EU, and key emerging markets? Yeah. So we spend a lot of time talking to our customers directly. And from everything that we're seeing and hearing, we don't see CapEx shifts by hospitals downward. We see increases, and we see opportunities, we believe, for our equipment to be purchased or leased depending on how they go about that. There are different acquisition models in different countries. But we haven't heard anything from the conversations that we're having with our various regions or customers specifically where they're concerned about the ability to buy equipment. It doesn't seem to be any shift or trend there that would work against us. All right. Great. Thank you very much. Again, if you have a question, please press star, then one. Again, that is star, then one. This concludes our question and answer session. I would like to turn the conference back over to Mr. Steve La Neve for any closing remarks. Please go ahead. Thank you all for joining our call today. We look forward to speaking with you again in May when we report our fiscal 2026 third-quarter earnings results. This concludes our earnings call. Thank you very much. The conference call has now concluded. Thank you for your participation. You may now disconnect. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C. Should you be buying ARAY right now? ProPicks AI evaluates ARAY alongside thousands of other companies every month using 100+ financial metrics . Using powerful AI to generate exciting stock ideas, it looks beyond popularity to assess fundamentals, momentum, and valuation. The AI has no bias—it simply identifies which stocks offer the best risk-reward based on current data with notable past winners that include Super Micro Computer (+185%) and AppLovin (+157%). Want to know if ARAY is currently featured in any ProPicks AI strategies, or if there are better opportunities in the same space?
  Content Reference URL	None

• Publisher

  Publisher Name	Investing.com (#43)
  Publisher URL	https://www.investing.com
  Description	None
  Trust Flow Score	37
  Citation Flow Score	46

• Data Source

  Data Source Name	NewsCatcher (#303)
  Data Source Type	news
  Data Source URL	https://www.newscatcherapi.com/
  Description
  Weight	1